Lee, Y.S., Bae, H.-J., Kang, D.-W., Lee, S.-H., Yu, K., Park, J.-M., Cho, Y.-J., Hong, K.-S., Kim, D.-E., Kwon, S.U., Lee, K.B., Rha, J.-H., Koo, J., Han, M.-G., Lee, S.J., Lee, J.-H., Jung, S.W., Lee, B.-C. and Kim, J.S. (2011) Cilostazol in Acute Ischemic Stroke Treatment (CAIST Trial): A Randomized Double-Blind Non-Inferiority Trial. Cerebrovascular Diseases, 32, 65-71.
http://dx.doi.org/10.1159/000327036

has been cited by the following article:

• TITLE: Intracranial Atherosclerosis: The Natural History and Management Strategies

  AUTHORS: Ossama Mansour, Martin Schumacher, Mohammad A. Farrag, Foad Abd-Allah

  KEYWORDS: Intracranial Atherosclerosis, Medical Therapy, Endovascular Treatment

  JOURNAL NAME: World Journal of Cardiovascular Diseases, Vol.4 No.7, June 12, 2014

  ABSTRACT: Intracranial atherosclerotic disease (ICAD) represents a major cause of stroke and transient ischemic attacks. The prevalence and natural course of ICAD are closely related to race and ethnicity. The best treatment for ICAD is a crucial issue; data from recent trials indicate that aggressive medical management and life style modifications are better than endovascular treatments for prevention of recurrent stroke in high-risk patients with ICAD. Endovascular treatment is still an option for subgroup of patients who are not responded to optimal medical therapy.